Respiratorius AB (publ) (XSAT:RESP)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.410
+0.050 (3.68%)
At close: Feb 25, 2026
Market Cap10.75M -74.0%
Revenue (ttm)n/a
Net Income-6.95M
EPS-1.17
Shares Out7.90M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,232
Average Volume30,249
Open1.360
Previous Close1.360
Day's Range1.345 - 1.430
52-Week Range1.190 - 10.500
Beta1.68
RSI42.53
Earnings DateFeb 10, 2026

About Respiratorius AB

Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company’s products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 0
Stock Exchange Spotlight Stock Market
Ticker Symbol RESP
Full Company Profile

Financial Performance

Financial Statements